Table 1.

Clinical characteristics of the 3 prostate cancer patient groups analyzed in this study

CharacteristicsVariablesAll FAM%a (n)UNS%b (n)SCRcase%c (n)
Average age at onsetAge at onset (y)62.868.667.0
Prostate specific antigen≤4.0 ng/mL5.4 (9)8.0 (234)12.9 (152)
4.1–9.9 ng/mL35.5 (59)43.0 (1,258)61.1 (719)
10.0–19.9 ng/mL26.5 (44)25.3 (740)17.9 (211)
20.0–49.9 ng/mL21.1 (35)13.3 (389)6.5 (77)
50.0–99.9 ng/mL4.8 (8)4.7 (137)0.8 (9)
≥100 ng/mL6.6 (11)5.7 (167)0.8 (9)
Missing data12.4 (24)8.5 (272)0.6 (7)
Primary treatmentProstatectomy46.0 (82)34.7 (1,030)23.0 (32)
Radiotherapy16.9 (30)18.4 (546)39.1 (55)
Hormonal therapy30.9 (55)37.9 (1,124)9.8 (14)
Active surveillance4.5 (8)5.6 (166)14.7 (21)
Brachytherapy1.7 (3)2.9 (86)12.6 (18)
Cystectomy0.5 (15)0.7 (1)
Missing data6.3 (12)7.2 (230)88.0 (1,043)
Gleason score for biopsy32.7 (4)2.7 (72)2.5 (29)
411.6 (17)4.1 (109)8.8 (102)
515.7 (23)11.4 (304)12.3 (143)
632.7 (48)36.5 (972)42.8 (496)
722.4 (33)27.8 (740)25.2 (292)
88.2 (12)8.4 (224)6.0 (70)
96.0 (9)8.4 (224)2.0 (23)
100.7 (1)0.7 (19)0.4 (5)
Missing data22.6 (43)16.7 (534)2.1 (25)
ProgressionPSA progression13.7 (26)30.9 (988)
Cause of deathOverall deaths42.1 (80)43.1 (1,378)8.8 (104)
Prostate cancer35.0 (67)26.6 (850)5.7 (67)
  • aAll FAM, familial index cases from all 190 Finnish prostate cancer families.

  • bUNS, unselected cases.

  • cSCRcase, screening trial cases.